Still cause for concern

Tattersfield, A.E.
September 1994
BMJ: British Medical Journal (International Edition);9/24/94, Vol. 309 Issue 6957, p794
Academic Journal
Focuses on the use of beta agonist on patients with asthma in the Great Britain. Mortality rate in the year 1960s and 1970s; Implication of high dosage of beta agonists on mortality rate from asthma; Suggestion of the morbidity study on the tolerance of beta agonist among asthma patients.


Related Articles

  • Adverse affects are not proved. Fuller, R.W. // BMJ: British Medical Journal (International Edition);9/24/94, Vol. 309 Issue 6957, p795 

    Focuses on the association of beta agonist to mortality rate from asthma. Acceptance of beta agonist as appropriate bronchodilator for asthma; Explanation on the association of beta agonist to mortality rate; Alternative hypothesis on the association of beta agonist to mortality rate. INSET:...

  • Asthma--The danger is real. Orsi, Allen J.; Moriarty, Mary-Beth // RN;Apr91, Vol. 54 Issue 4, p58 

    Presents guidelines on assessing and treating asthma. Reasons behind the increasing mortality rate for asthma; Details of the treatment process, including the use of aerosol beta-agonists; Information on the use of nebulized atropine sulfate for tough asthma cases. INSETS: How asthma obstructs...

  • Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma. Pauwels, Romain A.; Löfdahl, Claes-Göran; Postma, Dirkje S.; Tattersfield, Anne E.; O'Byrne, Paul; Barnes, Peter J.; Ullman, Anders // New England Journal of Medicine;11/13/97, Vol. 337 Issue 20, p1405 

    Background: The role of long-acting, inhaled β2-agonists in treating asthma is uncertain. In a double-blind study, we evaluated the effects of adding inhaled formoterol to both lower and higher doses of the inhaled glucocorticoid budesonide. Methods: After a four-week run-in period of...

  • Association between availability of non-prescriptions Beta [sub 2] agonist inhalers and undertreatment of asthma. Gibson, Peter; Henry, David; Francis, Lynn; Cruickshank, Duncan; Dupen, Fiona; Higginbotham, Nick; Henry, Richard; Sutherland, David // BMJ: British Medical Journal (International Edition);6/5/93, Vol. 306 Issue 6891, p1514 

    Examines the association between availability of non-prescription beta[sub 2] agonist inhalers and the undertreatment of asthma in pharmacies in New South Wales. Frequency of inhaler use; Adequacy of treatment according to published guidelines; Comparison of characteristics of patients in...

  • Tolerance due to long-acting beta agonists in asthma.  // American Family Physician;11/1/1995, Vol. 52 Issue 6, p1850 

    Reports on an article published by Grove and Lippworth in the July 22, 1995 issue of `Lancet' on the development of tolerance to long-acting beta-agonists in the treatment of asthma. Two-week washout period during which patients relied on ipratropium for relief of symptoms; Use of salmeterol or...

  • Update on asthma pharmacotherapy. Bell, Edward // Infectious Diseases in Children;Apr2009, Vol. 22 Issue 4, p14 

    The article offers information on the pharmacological management of asthma including beta agonists, inhaled corticosteroids and leukotriene modifiers.

  • COMPARATIVE STUDY OF EFFECTS TWO β2 ADRENERGIC AGONISTS ON BIOCHEMICAL PARAMETERS IN MODERATE TO SEVERE BRONCHIAL ASTHMA PATIENTS. Rathore, Kavita; Sharma, Neha; Aseri, M. L.; Mathur, Sunil Kumar; Sankhla, Sanjay // International Journal of Pharmaceutical Sciences & Research;Jun2013, Vol. 4 Issue 6, p2419 

    Background: β2- agonist drugs are frequently prescribed in asthmatics. Apart from bronchodilation they affect biochemical and physical parameters of the body. Method: Total 80 patients were divided into two groups. Group I (n=40) received Albuterol- 2.5mg./2.5ml. TDS and Group II (n=40)...

  • Best options for asthma treatment?  // PharmacoEconomics & Outcomes News;1/8/2011, Issue 619, p7 

    The article discusses two studies which examined the health care costs associated with the use of inhaled corticosteroid and long-acting Î’-agonist (ICS/LABA) combination products for the treatment of patients with mild asthma.

  • Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma. Beeh, Kai-Michael; LaForce, Craig; Gahlemann, Martina; Wenz, Arne; Toorawa, Robert; Fležar, Matjaž // Respiratory Research;Jul2015, Vol. 16 Issue 1, p1 

    Background: A Phase II, multicentre, randomised, double-blind, placebo-controlled, crossover trial comparing the 24-h forced expiratory volume in 1 s (FEV1) time profile after 3 weeks' treatment with once-daily (QD) or twice-daily (BID) olodaterol (at the same total daily dose) versus placebo...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics